reports
Pooya Hemami
- Pooya Hemami
Caladrius Biosciences - Cell therapy platforms for unmet need
Caladrius is developing cell therapy (CT) products that extract, expand and bolster a patient’s own (autologous) immune cells to treat diseases. CLBS03 is a potentially transformative Phase II candidate for recent-onset type I diabetes (TID), and CLBS14 and CLBS12 target ischemic injury conditions.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.